Related Experiment Video

Updated: Mar 21, 2026

Quantitative Examination of Antibiotic Susceptibility of Neisseria gonorrhoeae Aggregates Using ATP-utilization Commercial Assays and Live/Dead Staining

Quantitative Examination of Antibiotic Susceptibility of Neisseria gonorrhoeae Aggregates Using ATP-utilization Commercial Assays and Live/Dead Staining

Published on: February 8, 2019

Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria

Ronald N Jones¹, Kelley A Fedler², Nicole E Scangarella-Oman³

¹JMI Laboratories, North Liberty, Iowa, USA ronald-jones@jmilabs.com.

Antimicrobial Agents and Chemotherapy

|May 11, 2016

Abstract:

Gepotidacin, a novel triazaacenaphthylene antibacterial agent, is the first in a new class of type IIA topoisomerase inhibitors with activity against many biothreat and conventional pathogens, including Neisseria gonorrhoeae To assist ongoing clinical studies of gepotidacin to treat gonorrhea, a multilaboratory quality assurance investigation determined the reference organism (N. gonorrhoeae ATCC 49226) quality control MIC range to be 0.25 to 1 μg/ml (88.8% of gepotidacin MIC results at the 0.5 μg/ml mode).

More Related Videos

Metal-Limited Growth of Neisseria gonorrhoeae for Characterization of Metal-Responsive Genes and Metal Acquisition from Host Ligands

Metal-Limited Growth of Neisseria gonorrhoeae for Characterization of Metal-Responsive Genes and Metal Acquisition from Host Ligands

Published on: March 4, 2020

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids

Published on: May 4, 2018

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Characterization of isolates from two phase 3 uncomplicated urinary tract infection trials (EAGLE-2 and EAGLE-3) that show an apparent ≥4-fold increase in gepotidacin MIC between baseline and post-baseline visits.

JAC-antimicrobial resistance·2026

Characterization of gepotidacin activity, including in vitro kill kinetics, checkerboard, and PAE/SME testing against gram-positive and gram-negative bacteria.

Microbiology spectrum·2026

Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

In vitro antibacterial activity of gepotidacin in combination with other antimicrobial agents against Neisseria gonorrhoeae isolates.

Antimicrobial agents and chemotherapy·2026

Influence of different media and incubation times for determining the minimum inhibitory concentrations of gepotidacin, ciprofloxacin and ceftriaxone against Neisseria gonorrhoeae.

Diagnostic microbiology and infectious disease·2026

Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3.

Contemporary clinical trials communications·2025

See all related articles